A phase I multiple ascending dose study of ARGX-113

Trial Profile

A phase I multiple ascending dose study of ARGX-113

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs ARGX 113 (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 26 Oct 2016 According to an arGEN-X media release, complete data set from the study will be presented at American Society of Hematology (ASH) annual meeting.
    • 25 Aug 2016 According to an arGEN-X media release, complete data set from the study will be presented at argenx R&D day, 22 September 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top